Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-mesothelin CAR-IL-7-CCL19-expressing T lymphocytes TAK-103

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and simultaneously produce interleukin-7 (IL-7) and C-C motif chemokine 19 (CCL19), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-MSLN CAR-T cells TAK-103 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. IL-7 promotes the proliferation and survival of T cells. CCL19 enhances the migration of T cells and dendritic cells (DCs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-mesothelin CAR T Cells TAK-103
autologous anti-MSLN CAR T cells TAK-103
CAR T cells TAK-103
Code name:NIB 103
NIB-103
NIB103
TAK 103
TAK-103
TAK103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search